New Hope in Targeted Treatment for Lung Cancer

In patients with fourth-stage non-small cell lung cancer, that is, those who have developed metastasis , many targeted drugs have been developed over the last 10 years for treatment. Particularly in the adenocarcinoma subtype, more than half of patients who have never smoked were found eligible for targeted drug treatment, while this rate also reached around 20% in patients who smoked. It is extremely important to perform molecular tests in appropriate patients to determine whether targeted drugs will work, and new targets suitable for the use of targeted drugs are being discovered every day.
ESMO 2016 At the Cancer Congress, patients found to have RET fusion positivity in adenocarcinomas, a type of non-small cell lung cancer, were given the targeted drug Lenvatinib in a trial, and it was found to be very successful. Lenvatinib is a multikinase inhibitor and a drug that stops intracellular growth signals.
RET fusion positivity was detected in 1-2% of all adenocarcinomas. At first glance, these rates may seem very low and insignificant, but when one considers that this corresponds to a human life, its extreme importance becomes apparent.
Lenvatinib was used in 25 patients, and disease was brought under control in 76% of these patients. Although significant treatment-related side effects were observed, these side effects could be controlled, that is, managed, through dose adjustment. Although these study results are not yet sufficient to change our clinical practice, they herald a new ray of hope at our door.
Sources
Phase 2 study of lenvatinib (LN) in patients (Pts) with RET fusion-positive adenocarcinoma of the lung.
ESMO 2016, 1204PD
Was this article helpful?
Your feedback helps us improve our content.




Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.